IBDEI0Q3 ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,11727,1,4,0)
;;=4^N02.2
;;^UTILITY(U,$J,358.3,11727,2)
;;=^5015513
;;^UTILITY(U,$J,358.3,11728,0)
;;=N02.3^^46^573^73
;;^UTILITY(U,$J,358.3,11728,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11728,1,3,0)
;;=3^Recur & perst hematur w/ diffus mesangial prolif glomrlneph
;;^UTILITY(U,$J,358.3,11728,1,4,0)
;;=4^N02.3
;;^UTILITY(U,$J,358.3,11728,2)
;;=^5015514
;;^UTILITY(U,$J,358.3,11729,0)
;;=N02.4^^46^573^72
;;^UTILITY(U,$J,358.3,11729,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11729,1,3,0)
;;=3^Recur & perst hematur w/ diffus endocaplry prolif glomrlneph
;;^UTILITY(U,$J,358.3,11729,1,4,0)
;;=4^N02.4
;;^UTILITY(U,$J,358.3,11729,2)
;;=^5015515
;;^UTILITY(U,$J,358.3,11730,0)
;;=N02.5^^46^573^77
;;^UTILITY(U,$J,358.3,11730,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11730,1,3,0)
;;=3^Recurrent & perst hematur w/ diffuse mesangiocap glomrlneph
;;^UTILITY(U,$J,358.3,11730,1,4,0)
;;=4^N02.5
;;^UTILITY(U,$J,358.3,11730,2)
;;=^5015516
;;^UTILITY(U,$J,358.3,11731,0)
;;=N02.6^^46^573^74
;;^UTILITY(U,$J,358.3,11731,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11731,1,3,0)
;;=3^Recurrent & perst hematur w/ dense deposit disease
;;^UTILITY(U,$J,358.3,11731,1,4,0)
;;=4^N02.6
;;^UTILITY(U,$J,358.3,11731,2)
;;=^5015517
;;^UTILITY(U,$J,358.3,11732,0)
;;=N02.7^^46^573^75
;;^UTILITY(U,$J,358.3,11732,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11732,1,3,0)
;;=3^Recurrent & perst hematur w/ diffuse crescentic glomrlneph
;;^UTILITY(U,$J,358.3,11732,1,4,0)
;;=4^N02.7
;;^UTILITY(U,$J,358.3,11732,2)
;;=^5015518
;;^UTILITY(U,$J,358.3,11733,0)
;;=N02.8^^46^573^80
;;^UTILITY(U,$J,358.3,11733,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11733,1,3,0)
;;=3^Recurrent & perst hematur w/ oth morphologic changes
;;^UTILITY(U,$J,358.3,11733,1,4,0)
;;=4^N02.8
;;^UTILITY(U,$J,358.3,11733,2)
;;=^5015519
;;^UTILITY(U,$J,358.3,11734,0)
;;=N02.9^^46^573^81
;;^UTILITY(U,$J,358.3,11734,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11734,1,3,0)
;;=3^Recurrent & perst hematur w/ unsp morphologic changes
;;^UTILITY(U,$J,358.3,11734,1,4,0)
;;=4^N02.9
;;^UTILITY(U,$J,358.3,11734,2)
;;=^5015520
;;^UTILITY(U,$J,358.3,11735,0)
;;=N03.0^^46^573^18
;;^UTILITY(U,$J,358.3,11735,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11735,1,3,0)
;;=3^Chr nephritic syndrome w/ minor glomerular abnormality
;;^UTILITY(U,$J,358.3,11735,1,4,0)
;;=4^N03.0
;;^UTILITY(U,$J,358.3,11735,2)
;;=^5015521
;;^UTILITY(U,$J,358.3,11736,0)
;;=N03.1^^46^573^17
;;^UTILITY(U,$J,358.3,11736,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11736,1,3,0)
;;=3^Chr nephritic syndrome w/ focal & seg glomerular lesions
;;^UTILITY(U,$J,358.3,11736,1,4,0)
;;=4^N03.1
;;^UTILITY(U,$J,358.3,11736,2)
;;=^5015522
;;^UTILITY(U,$J,358.3,11737,0)
;;=N03.2^^46^573^14
;;^UTILITY(U,$J,358.3,11737,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11737,1,3,0)
;;=3^Chr nephritic syndrome w/ diffuse membranous glomrlneph
;;^UTILITY(U,$J,358.3,11737,1,4,0)
;;=4^N03.2
;;^UTILITY(U,$J,358.3,11737,2)
;;=^5015523
;;^UTILITY(U,$J,358.3,11738,0)
;;=N03.3^^46^573^15
;;^UTILITY(U,$J,358.3,11738,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11738,1,3,0)
;;=3^Chr nephritic syndrome w/ diffuse mesangial prolif glomrlneph
;;^UTILITY(U,$J,358.3,11738,1,4,0)
;;=4^N03.3
;;^UTILITY(U,$J,358.3,11738,2)
;;=^5015524
;;^UTILITY(U,$J,358.3,11739,0)
;;=N03.4^^46^573^13
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI0Q3 3786 printed Apr 09, 2024@21:30:45 Page 2
IBDEI0Q3 ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,11727,1,4,0)
+2 ;;=4^N02.2
+3 ;;^UTILITY(U,$J,358.3,11727,2)
+4 ;;=^5015513
+5 ;;^UTILITY(U,$J,358.3,11728,0)
+6 ;;=N02.3^^46^573^73
+7 ;;^UTILITY(U,$J,358.3,11728,1,0)
+8 ;;=^358.31IA^4^2
+9 ;;^UTILITY(U,$J,358.3,11728,1,3,0)
+10 ;;=3^Recur & perst hematur w/ diffus mesangial prolif glomrlneph
+11 ;;^UTILITY(U,$J,358.3,11728,1,4,0)
+12 ;;=4^N02.3
+13 ;;^UTILITY(U,$J,358.3,11728,2)
+14 ;;=^5015514
+15 ;;^UTILITY(U,$J,358.3,11729,0)
+16 ;;=N02.4^^46^573^72
+17 ;;^UTILITY(U,$J,358.3,11729,1,0)
+18 ;;=^358.31IA^4^2
+19 ;;^UTILITY(U,$J,358.3,11729,1,3,0)
+20 ;;=3^Recur & perst hematur w/ diffus endocaplry prolif glomrlneph
+21 ;;^UTILITY(U,$J,358.3,11729,1,4,0)
+22 ;;=4^N02.4
+23 ;;^UTILITY(U,$J,358.3,11729,2)
+24 ;;=^5015515
+25 ;;^UTILITY(U,$J,358.3,11730,0)
+26 ;;=N02.5^^46^573^77
+27 ;;^UTILITY(U,$J,358.3,11730,1,0)
+28 ;;=^358.31IA^4^2
+29 ;;^UTILITY(U,$J,358.3,11730,1,3,0)
+30 ;;=3^Recurrent & perst hematur w/ diffuse mesangiocap glomrlneph
+31 ;;^UTILITY(U,$J,358.3,11730,1,4,0)
+32 ;;=4^N02.5
+33 ;;^UTILITY(U,$J,358.3,11730,2)
+34 ;;=^5015516
+35 ;;^UTILITY(U,$J,358.3,11731,0)
+36 ;;=N02.6^^46^573^74
+37 ;;^UTILITY(U,$J,358.3,11731,1,0)
+38 ;;=^358.31IA^4^2
+39 ;;^UTILITY(U,$J,358.3,11731,1,3,0)
+40 ;;=3^Recurrent & perst hematur w/ dense deposit disease
+41 ;;^UTILITY(U,$J,358.3,11731,1,4,0)
+42 ;;=4^N02.6
+43 ;;^UTILITY(U,$J,358.3,11731,2)
+44 ;;=^5015517
+45 ;;^UTILITY(U,$J,358.3,11732,0)
+46 ;;=N02.7^^46^573^75
+47 ;;^UTILITY(U,$J,358.3,11732,1,0)
+48 ;;=^358.31IA^4^2
+49 ;;^UTILITY(U,$J,358.3,11732,1,3,0)
+50 ;;=3^Recurrent & perst hematur w/ diffuse crescentic glomrlneph
+51 ;;^UTILITY(U,$J,358.3,11732,1,4,0)
+52 ;;=4^N02.7
+53 ;;^UTILITY(U,$J,358.3,11732,2)
+54 ;;=^5015518
+55 ;;^UTILITY(U,$J,358.3,11733,0)
+56 ;;=N02.8^^46^573^80
+57 ;;^UTILITY(U,$J,358.3,11733,1,0)
+58 ;;=^358.31IA^4^2
+59 ;;^UTILITY(U,$J,358.3,11733,1,3,0)
+60 ;;=3^Recurrent & perst hematur w/ oth morphologic changes
+61 ;;^UTILITY(U,$J,358.3,11733,1,4,0)
+62 ;;=4^N02.8
+63 ;;^UTILITY(U,$J,358.3,11733,2)
+64 ;;=^5015519
+65 ;;^UTILITY(U,$J,358.3,11734,0)
+66 ;;=N02.9^^46^573^81
+67 ;;^UTILITY(U,$J,358.3,11734,1,0)
+68 ;;=^358.31IA^4^2
+69 ;;^UTILITY(U,$J,358.3,11734,1,3,0)
+70 ;;=3^Recurrent & perst hematur w/ unsp morphologic changes
+71 ;;^UTILITY(U,$J,358.3,11734,1,4,0)
+72 ;;=4^N02.9
+73 ;;^UTILITY(U,$J,358.3,11734,2)
+74 ;;=^5015520
+75 ;;^UTILITY(U,$J,358.3,11735,0)
+76 ;;=N03.0^^46^573^18
+77 ;;^UTILITY(U,$J,358.3,11735,1,0)
+78 ;;=^358.31IA^4^2
+79 ;;^UTILITY(U,$J,358.3,11735,1,3,0)
+80 ;;=3^Chr nephritic syndrome w/ minor glomerular abnormality
+81 ;;^UTILITY(U,$J,358.3,11735,1,4,0)
+82 ;;=4^N03.0
+83 ;;^UTILITY(U,$J,358.3,11735,2)
+84 ;;=^5015521
+85 ;;^UTILITY(U,$J,358.3,11736,0)
+86 ;;=N03.1^^46^573^17
+87 ;;^UTILITY(U,$J,358.3,11736,1,0)
+88 ;;=^358.31IA^4^2
+89 ;;^UTILITY(U,$J,358.3,11736,1,3,0)
+90 ;;=3^Chr nephritic syndrome w/ focal & seg glomerular lesions
+91 ;;^UTILITY(U,$J,358.3,11736,1,4,0)
+92 ;;=4^N03.1
+93 ;;^UTILITY(U,$J,358.3,11736,2)
+94 ;;=^5015522
+95 ;;^UTILITY(U,$J,358.3,11737,0)
+96 ;;=N03.2^^46^573^14
+97 ;;^UTILITY(U,$J,358.3,11737,1,0)
+98 ;;=^358.31IA^4^2
+99 ;;^UTILITY(U,$J,358.3,11737,1,3,0)
+100 ;;=3^Chr nephritic syndrome w/ diffuse membranous glomrlneph
+101 ;;^UTILITY(U,$J,358.3,11737,1,4,0)
+102 ;;=4^N03.2
+103 ;;^UTILITY(U,$J,358.3,11737,2)
+104 ;;=^5015523
+105 ;;^UTILITY(U,$J,358.3,11738,0)
+106 ;;=N03.3^^46^573^15
+107 ;;^UTILITY(U,$J,358.3,11738,1,0)
+108 ;;=^358.31IA^4^2
+109 ;;^UTILITY(U,$J,358.3,11738,1,3,0)
+110 ;;=3^Chr nephritic syndrome w/ diffuse mesangial prolif glomrlneph
+111 ;;^UTILITY(U,$J,358.3,11738,1,4,0)
+112 ;;=4^N03.3
+113 ;;^UTILITY(U,$J,358.3,11738,2)
+114 ;;=^5015524
+115 ;;^UTILITY(U,$J,358.3,11739,0)
+116 ;;=N03.4^^46^573^13
